Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ROSG's Cash to Debt is ranked higher than
100% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. ROSG: No Debt )
ROSG' s 10-Year Cash to Debt Range
Min: 0.77   Max: No Debt
Current: No Debt

Equity to Asset 0.91
ROSG's Equity to Asset is ranked higher than
95% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. ROSG: 0.91 )
ROSG' s 10-Year Equity to Asset Range
Min: -0.27   Max: 0.95
Current: 0.91

-0.27
0.95
F-Score: 3
Z-Score: 3.40
M-Score: -2.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1816.84
ROSG's Operating margin (%) is ranked higher than
50% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. ROSG: -1816.84 )
ROSG' s 10-Year Operating margin (%) Range
Min: -9864.67   Max: -3295.56
Current: -1816.84

-9864.67
-3295.56
Net-margin (%) -1800.00
ROSG's Net-margin (%) is ranked higher than
50% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. ROSG: -1800.00 )
ROSG' s 10-Year Net-margin (%) Range
Min: -11003.33   Max: -3184.44
Current: -1800

-11003.33
-3184.44
ROE (%) -57.89
ROSG's ROE (%) is ranked higher than
55% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ROSG: -57.89 )
ROSG' s 10-Year ROE (%) Range
Min: -545.27   Max: -47.3
Current: -57.89

-545.27
-47.3
ROA (%) -53.14
ROSG's ROA (%) is ranked higher than
56% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.94 vs. ROSG: -53.14 )
ROSG' s 10-Year ROA (%) Range
Min: -286.59   Max: -40.87
Current: -53.14

-286.59
-40.87
ROC (Joel Greenblatt) (%) -1768.36
ROSG's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. ROSG: -1768.36 )
ROSG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1879.86   Max: -966.63
Current: -1768.36

-1879.86
-966.63
Revenue Growth (3Y)(%) -65.70
ROSG's Revenue Growth (3Y)(%) is ranked higher than
54% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. ROSG: -65.70 )
ROSG' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -57.7
Current: -65.7

EBITDA Growth (3Y)(%) -68.90
ROSG's EBITDA Growth (3Y)(%) is ranked higher than
52% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. ROSG: -68.90 )
ROSG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -4.6
Current: -68.9

EPS Growth (3Y)(%) -68.90
ROSG's EPS Growth (3Y)(%) is ranked higher than
52% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. ROSG: -68.90 )
ROSG' s 10-Year EPS Growth (3Y)(%) Range
Min: -68.9   Max: 45.9
Current: -68.9

-68.9
45.9
» ROSG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ROSG Guru Trades in

ROSG Guru Trades in

Q3 2014

ROSG Guru Trades in Q3 2014

Jim Simons 18,400 sh (New)
» More
Q4 2014

ROSG Guru Trades in Q4 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ROSG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.80
ROSG's P/B is ranked higher than
89% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. ROSG: 1.80 )
ROSG' s 10-Year P/B Range
Min: 0.73   Max: 4.84
Current: 1.8

0.73
4.84
P/S 81.40
ROSG's P/S is ranked higher than
55% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.52 vs. ROSG: 81.40 )
ROSG' s 10-Year P/S Range
Min: 3.33   Max: 209.09
Current: 81.4

3.33
209.09
EV-to-EBIT -0.94
ROSG's EV-to-EBIT is ranked higher than
51% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ROSG: -0.94 )
ROSG' s 10-Year EV-to-EBIT Range
Min: -2.6   Max: 2.4
Current: -0.94

-2.6
2.4
Current Ratio 12.90
ROSG's Current Ratio is ranked higher than
96% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. ROSG: 12.90 )
ROSG' s 10-Year Current Ratio Range
Min: 0.65   Max: 25.08
Current: 12.9

0.65
25.08
Quick Ratio 12.90
ROSG's Quick Ratio is ranked higher than
96% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. ROSG: 12.90 )
ROSG' s 10-Year Quick Ratio Range
Min: 0.65   Max: 25.08
Current: 12.9

0.65
25.08
Days Sales Outstanding 211.57
ROSG's Days Sales Outstanding is ranked higher than
60% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 81.46 vs. ROSG: 211.57 )
ROSG' s 10-Year Days Sales Outstanding Range
Min: 66.72   Max: 885.73
Current: 211.57

66.72
885.73

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.55
ROSG's Price/Net Cash is ranked higher than
99% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ROSG: 1.55 )
ROSG' s 10-Year Price/Net Cash Range
Min: 1.31   Max: 7.58
Current: 1.55

1.31
7.58
Price/Net Current Asset Value 1.52
ROSG's Price/Net Current Asset Value is ranked higher than
99% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ROSG: 1.52 )
ROSG' s 10-Year Price/Net Current Asset Value Range
Min: 1.14   Max: 5.01
Current: 1.52

1.14
5.01
Price/Tangible Book 1.85
ROSG's Price/Tangible Book is ranked higher than
93% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.30 vs. ROSG: 1.85 )
ROSG' s 10-Year Price/Tangible Book Range
Min: 1.02   Max: 3.68
Current: 1.85

1.02
3.68
Price/Median PS Value 1.15
ROSG's Price/Median PS Value is ranked higher than
72% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. ROSG: 1.15 )
ROSG' s 10-Year Price/Median PS Value Range
Min: 0.19   Max: 2.23
Current: 1.15

0.19
2.23
Earnings Yield (Greenblatt) -107.50
ROSG's Earnings Yield (Greenblatt) is ranked lower than
55% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. ROSG: -107.50 )
ROSG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 41.5   Max: 7936.1
Current: -107.5

41.5
7936.1

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:RQ1.Germany,
Rosetta Genomics, Ltd., develops diagnostic tests and therapeutic tools. Its product portfolio comprises of tests such as miRview mets2/mets, miRview squamous, miRview meso and miRview kidney.
» More Articles for ROSG

Headlines

Articles On GuruFocus.com
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance Nov 18 2014 
Rosetta Genomics Reports Second Quarter Financial Results, Provides Business Update Sep 08 2009 
Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd. Jan 08 2009 
Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $ Dec 08 2008 

More From Other Websites
Nasdaq stocks posting largest volume increases Mar 05 2015
Rosetta Genomics to Present at the 27th Annual ROTH Conference Mar 04 2015
Rosetta Genomics to Present at the 27th Annual ROTH Conference Mar 04 2015
Rosetta Genomics’ Novel and Differentiated Thyroid Cancer Assay Moves to Advanced Stages of... Feb 26 2015
Rosetta Genomics’ Novel and Differentiated Thyroid Cancer Assay Moves to Advanced Stages of... Feb 26 2015
ROSG: Broad Patent Allowances Assure Sustainable Growth Feb 20 2015
Rosetta Genomics (ROSG) Stock Sells Off Today Following Tuesday's Surge Feb 18 2015
One ETF Gets a Lift From Rosetta Genomics Feb 17 2015
Rosetta Genomics (ROSG) Stock Soars Today After Patent Allowance Announcements Feb 17 2015
Rosetta Genomics Announces Key Patent Allowances in U.S. and Europe Feb 17 2015
Rosetta Genomics Announces Key Patent Allowances in U.S. and Europe Feb 17 2015
Rosetta Genomics Receives First Patent Allowance in Japan Feb 10 2015
Rosetta Genomics Receives First Patent Allowance in Japan Feb 10 2015
Rosetta Genomics Announces Commercial Partnership with Precipio Diagnostics Feb 09 2015
Rosetta Genomics Announces Commercial Partnership with Precipio Diagnostics Feb 09 2015
Clinician Survey Supporting Value Proposition of the Rosetta Kidney Cancer Test™ Published in the... Jan 20 2015
Clinician Survey Supporting Value Proposition of the Rosetta Kidney Cancer Test™ Published in the... Jan 20 2015
Rosetta Genomics Issues Letter to Shareholders Jan 12 2015
Rosetta Genomics Issues Letter to Shareholders Jan 12 2015
Rosetta Genomics Announces Launch of Admera Health’s Sequencing-Based Oncology Tests Jan 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK